SpaceX Lines Up April Investor Briefings as IPO Questions Swirl
SpaceX is telling prospective IPO investors to expect briefings in April from company executives, according to people familiar with the matter, as advisers scramble to file for potentially the biggest listing of all time.
More in Pivot Invest
Fact or fiction: Exploring the reality of AI in payments testing
Exploring the expectations and realities of AI in payments testing.
Patch and perish: The hidden risks of incremental payment modernisation
What strategic capabilities must executives invest in now to prevent today’s rising real-time volumes from becoming tomorrow’s systemic or reputational failures?
2026 US ACH rules: Impact on RTP, FedNow and fraud controls
What new fraud threats or behaviours will matter most in 2026, and how should banks and fintechs respond?
Halter says it’s not an agtech company on the heels of $220m Series E
Virtual fencing systems like those of Halter are about much more than simply replacing physical infrastructure on the ranch. The post Halter says it’s not an agtech company on the heels of $220m Series E appeared first on AgFunderNews.
More from Pivot News
Beyond connectivity and ISO 20022 compliance: How to reduce TCO and unlock value
How can unified, enriched payment data support better risk analysis, operational optimisation, liquidity visibility, and more informed decision-making?
FDA Approval for Denali Therapeutics Blazes a New Trail for Brain-Penetrating Drugs
Denali Therapeutics’ Avlayah received FDA approval for treating Hunter syndrome, a rare neurological disorder. The biologic medicine uses Denali’s proprietary drug delivery technology to cross the protective blood-brain barrier. The post FDA Approval for Denali Therapeutics Blazes a New Trail for Brain-Penetrating Drugs appeared first on MedCity News.